Table 2 Expression of pS 21 GSK3α/pS 9 GSK3β in various OTSCC and control tissue samples and their correlation with clinico-pathological parameters
Sl. No. | Groups | Total (N = 57) | pS 21 GSK3α | pS 9 GSK3β | p-value (pS 9 GSK3β over pS 21 GSK3α ) | |||
|---|---|---|---|---|---|---|---|---|
Expression | Overexpression | Expression | Overexpression | Expression | Overexpression | |||
1 | Age | |||||||
≤40 | 8 | 04 (50.0%) | 03 (37.5%) | 06 (75.0%) | 04 (50.0%) | NS | NS | |
>40 ≤ 70 | 42 | 29 (69.0%) | 12 (27.9%) | 37 (88.0%) | 30 (71.4%) | NS | 0.0002 | |
>70 | 07 | 05 (71.4%) | 03 (42.8%) | 06 (85.7%) | 05 (71.4%) | NS | NS | |
2 | Sex | |||||||
Male | 34 | 22 (64.7%) | 09 (26.4%) | 29 (94.5%) | 22 (64.7%) | NS | 0.0032 | |
Female | 23 | 16 (69.5%) | 09 (39.1%) | 20 (91.3%) | 17 (73.9%) | NS | 0.036 | |
3 | Histological grade | |||||||
WDSCC | 37 | 29 (78.3%) | 17 (45.9%) | 37 (100%) | 32 (86.4%) | 0.01 | 0.0004 | |
MDSCC | 06 | 03 (50.0%) | 01 (16.6%) | 06 (100%) | 02 (33.3%) | 0.01 | NS | |
PDSCC | 05 | 02 (40.0%) | 00 (00.0%) | 03 (60.0%) | 03 (60.0%) | NS | NS | |
4 | Size | |||||||
T1-T2 | 44 | 31 (70.4%) | 17 (36.1%) | 41 (93.6%) | 34 (77.2%) | 0.01 | 0.0005 | |
T3-T4 | 06 | 04 (66.6%) | 01 (16.6%) | 06 (100%) | 04 (66.6%) | NS | NS | |
5 | Lymph nodes | |||||||
N0 | 47 | 33 (70.2%) | 18 (38.2%) | 44 (93.6%) | 37 (78.7%) | 0.006 | 0.005 | |
N1-N3 | 03 | 02 (66.6%) | 00 (100%) | 03 (100%) | 01 (33.3%) | NS | NS | |
6 | Distant Metastasis | |||||||
M0 | 50 | 35 (70.0%) | 18 (36.0%) | 47 (94.0% | 38 (76.0%) | 0.003 | 0.0001 | |
M1 | 00 | 00 (00.0%) | 00 (00.0%) | 00 (00.0%) | 00 (00.0%) | NA | NA | |
7 | Tissue types | |||||||
OSCC (Tongue) | 50 | 35 (70.0%) | 18 (36.0%) | 47 (94.0% | 38 (76.0%) | 0.003 | 0.0001 | |
Normal Tongue (Cancer adjacent) | 7 | 03 (42.8%) | 00 (00.0%) | 02 (28.5%) | 01 (14.2%) | NS | NS | |